Altered circulating levels of matrix metalloproteinases and inhibitors associated with elevated type 2 cytokines in lymphatic filarial disease

PLoS Neglected Tropical Diseases

Volumn 6, Issue 6, 2012, Pages

  Anuradha, Rajamanickam ^a   George, Jovvian P ^a   Pavankumar, Nathella ^a   Kumaraswami, Vasanthapuram ^b   Nutman, Thomas B ^c   Babu, Subash ^a,d  

^a National Institutes of Health International Center for Excellence in Research   (India)

^b NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERLEUKIN 13; INTERLEUKIN 5; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHATIC FILARIASIS; MAJOR CLINICAL STUDY; MALE; ANIMAL; BLOOD; CHEMISTRY; MIDDLE AGED; PATHOLOGY; PLASMA;

ADOLESCENT; ADULT; AGED; ANIMALS; CYTOKINES; ELEPHANTIASIS, FILARIAL; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PLASMA; TISSUE INHIBITOR OF METALLOPROTEINASES; YOUNG ADULT;

EID: 84863667209     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001681     Document Type: Article

References (42)

1. Nutman TB, Kumaraswami V, (2001) Regulation of the immune response in lymphatic filariasis: perspectives on acute and chronic infection with Wuchereria bancrofti in South India. Parasite Immunol 23: 389-399.
2. Pfarr KM, Debrah AY, Specht S, Hoerauf A, (2009) Filariasis and lymphoedema. Parasite Immunol 31: 664-672.
3. Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF, (2000) Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today 16: 544-548.
4. Figueredo-Silva J, Noroes J, Cedenho A, Dreyer G, (2002) The histopathology of bancroftian filariasis revisited: the role of the adult worm in the lymphatic-vessel disease. Ann Trop Med Parasitol 96: 531-541.
5. Taylor MJ, (2003) Wolbachia in the inflammatory pathogenesis of human filariasis. Ann N Y Acad Sci 990: 444-449.
6. Bennuru S, Nutman TB, (2009) Lymphatics in human lymphatic filariasis: in vitro models of parasite-induced lymphatic remodeling. Lymphat Res Biol 7: 215-219.
7. el-Sharkawy IM, Haseeb AN, Saleh WA, (2001) Serum levels of endothelin-1 (ET-1), interleukin-2 (IL-2) and amino-terminal propeptide type III procollagen (PIII NP) in patients with acute and chronic filariasis. J Egypt Soc Parasitol 31: 169-176.
8. Esterre P, Plichart C, Huin-Blondey MO, Nguyen LN, Hartmann D, et al. (2006) Circulating fibrosis markers, eosinophil cationic protein and eosinophil protein X in patients with Wuchereria bancrofti infection: association with clinical status. Parasite 13: 165-170.
9. Fleming-Hubertz S, Simonsen PE, Jensen LT, (1997) Circulating connective tissue metabolites in patients with bancroftian filariasis. Trans R Soc Trop Med Hyg 91: 442-445.
10. Allen JE, Maizels RM, (2011) Diversity and dialogue in immunity to helminths. Nat Rev Immunol 11: 375-388.
11. Wynn TA, (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117: 524-529.
12. Amalinei C, Caruntu ID, Giusca SE, Balan RA, (2010) Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol 51: 215-228.
13. Clark IM, Swingler TE, Sampieri CL, Edwards DR, (2008) The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40: 1362-1378.
14. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO, (2011) Regulation of matrix metalloproteinase activity in health and disease. FEBS J 278: 28-45.
15. Elkington PT, O'Kane CM, Friedland JS, (2005) The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 142: 12-20.
16. Gialeli C, Theocharis AD, Karamanos NK, (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27.
17. Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, et al. (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 26: 251-58.
18. Murphy G, Nagase H, (2008) Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 4: 128-135.
19. Arthur MJ, (2000) Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 279: G245-249.
20. Toubi E, Kessel A, Grushko G, Sabo E, Rozenbaum M, et al. (2002) The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 20: 221-224.
21. Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, et al. (2001) Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis 60: 846-851.
22. Verma A, Prasad KN, Nyati KK, Singh SK, Singh AK, et al. (2011) Association of MMP-2 and MMP-9 with clinical outcome of neurocysticercosis. Parasitology 138: 1423-428.
23. Maretti-Mira AC, de Pinho Rodrigues KM, de Oliveira-Neto MP, Pirmez C, Craft N, (2011) MMP-9 activity is induced by Leishmania braziliensis infection and correlates with mucosal leishmaniasis. Acta Trop 119: 160-164.
24. Gomez DE, De Lorenzo MS, Alonso DF, Andrade ZA, (1999) Expression of metalloproteinases (MMP-1, MMP-2, and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in schistosomal portal fibrosis. Am J Trop Med Hyg 61: 9-13.
25. Tsai HC, Chung LY, Chen ER, Liu YC, Lee SS, et al. (2008) Association of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-4 in cerebrospinal fluid with blood-brain barrier dysfunction in patients with eosinophilic meningitis caused by Angiostrongylus cantonensis. Am J Trop Med Hyg 78: 20-27.
26. Geurts N, Opdenakker G, Van den Steen PE, (2012) Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol Ther 133: 257-279.
27. Moore CS, Crocker SJ, (2012) An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 180: 12-16.
28. Niebroj-Dobosz I, Janik P, Sokolowska B, Kwiecinski H, (2010) Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur J Neurol 17: 226-231.
29. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, et al. (2005) Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 96: 339-345.
30. Salata IM, Stojanovic N, Cajdler-Luba A, Lewandowski KC, Lewinski A, (2008) Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis. Gynecol Endocrinol 24: 326-330.
31. Koulentaki M, Valatas V, Xidakis K, Kouroumalis A, Petinaki E, et al. (2002) Matrix metalloproteinases and their inhibitors in acute viral hepatitis. J Viral Hepat 9: 189-193.
32. Hu J, Van den Steen PE, Sang QX, Opdenakker G, (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6: 480-498.
33. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, et al. (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9: 407-415.
34. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, et al. (2003) TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114: 171-180.
35. Kang HR, Cho SJ, Lee CG, Homer RJ, Elias JA, (2007) Transforming growth factor (TGF)-β1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12. J Biol Chem 282: 7723-7732.
36. Lanone S, Zheng T, Zhu Z, Liu W, Lee CG, et al. (2002) Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and-12 in IL-13-induced inflammation and remodeling. J Clin Invest 110: 463-474.
37. Sandler NG, Mentink-Kane MM, Cheever AW, Wynn TA, (2003) Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for Th1 and Th2 responses in tissue repair. J Immunol 171: 3655-3667.
38. Wynn TA, (2004) Fibrotic disease and the TH1/TH2 paradigm. Nat Rev Immunol 4: 583-594.
39. Singh KP, Gerard HC, Hudson AP, Boros DL, (2004) Dynamics of collagen, MMP and TIMP gene expression during the granulomatous, fibrotic process induced by Schistosoma mansoni eggs. Ann Trop Med Parasitol 98: 581-593.
40. Singh KP, Gerard HC, Hudson AP, Boros DL, (2004) Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice. Immunology 111: 343-352.
41. Singh KP, Gerard HC, Hudson AP, Boros DL, (2006) Differential expression of collagen, MMP, TIMP and fibrogenic-cytokine genes in the granulomatous colon of Schistosoma mansoni-infected mice. Ann Trop Med Parasitol 100: 611-20.
42. Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA, (2001) Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 167: 7017-7026.